RxDoctor Payments DataLook up a doctor →

Karen Gross

Adult Health · Washington, MONPI 1518170596

Payments from drug & device makers

$9,029in general payments, 2019–2025

Across 514 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Otsuka America Pharmaceutical, Inc.$780
  • Novo Nordisk$576
  • Boehringer Ingelheim$445
  • Amgen$405
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,94999%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,029 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$50,227
Medicare patients
282
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$58,380
MounjaroTirzepatide26$43,167
JardianceEmpagliflozin29$36,510
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$34,811
OzempicSemaglutide21$28,935
XareltoRivaroxaban25$23,299
FarxigaDapagliflozin Propanediol19$21,351
RexultiBrexpiprazole13$17,146
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,922
ArexvyRsvpref3 Antigen/As01e/Pf30$8,358
MyrbetriqMirabegron11$5,810
Duloxetine Hcl139$3,288
Omeprazole130$2,254
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,946
Gabapentin76$1,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$351$58,38060 claims
GSKTrelegy Ellipta, Arexvy$287$43,16976 claims
Lilly USA, LLCMounjaro$360$43,16726 claims
Boehringer IngelheimJardiance$445$36,51029 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,115$35,27440 claims
Novo NordiskOzempic$576$28,93521 claims
Johnson & JohnsonXarelto$56$23,29925 claims
Otsuka America Pharmaceutical, Inc.Rexulti$780$17,14613 claims
Astellas Pharma US IncMyrbetriq$35$5,81011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.

Other adult health in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →